nach oben

Endocrine

Erschienen in:

02.05.2018 | Review

The emerging role of aldosterone/mineralocorticoid receptors in the pathogenesis of erectile dysfunction

verfasst von: Fei Wu, Yun Lin, Qingyong Liu

Erschienen in: Endocrine | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Aldosterone is an old hormone that has been discovered for more than fifty years. The clinical application of its receptors' inhibitors, especially spirolactone, has benifited patients for decades worldwide. In this review, we briefly summarized the molecular mechanism of aldosterone/mineralocorticoid receptors (Ald-MRs) signaling in cardiovascular diseases and its emerging role in erectile dysfunction.

Methods

We searched PubMed, Web of Science, and Scopus for manuscripts published prior to December 2017 using key words " aldosterone " AND " erectile dysfunction " OR " cardiovascular disease " OR " mineralocorticoid receptors ". Related literature and clinical perspectives were collated, summarized and discussed in this review.

Results

The increase of reactive oxygen species production, inhibition of endothelial nitric oxide synthase system, and induction of inflammation are ubiquitous in vascular endothelial cells or vascular smooth muscle cells after the activation of Ald-MRs pathway. In addition, in cardiovascular diseases with over-active Ald-MRs signaling, MRs blockade could reverse the injury and improve the prognosis. Notably, multiple studies have correlated aldosterone and MRs to the pathogenesis of erectile function, while the mechanism is largely unperfectly identified.

Conclusion

In conclusion, we summarize the current evidence to highlight the potential role of aldosterone in erectile dysfunction and provide critical insights into the treatment of the disease.

B.C. Rossier, M.E. Baker, R.A. Studerr, Epithelial sodium transport and its control by aldosterone: the story of our internal environment revisited. Physiol. Rev. 95, 297–340 (2015)PubMedCrossRef

P.J. Fuller, Y. Yao, J. Yang, M.J. Young, Mechanisms of ligand specificity of the mineralocorticoid receptor. J. Endocrinol. 213, 15–24 (2012)PubMedCrossRef

F. Jaisser, N. Farman, Emerging roles of the mineralocorticoid receptor in pathology: toward new paradigms in clinical pharmacology. Pharmacol. Rev. 68, 49–75 (2016)PubMedCrossRef

J.W. Funder, The role of aldosterone and mineralocorticoid receptors in cardiovascular disease. Am. J. Cardiovasc. Drugs 7, 151–157 (2007)PubMedCrossRef

M. Heinrich, J.M. Prieto, Diet and healthy ageing 2100: will we globalise local knowledge systems? Ageing Res. Rev. 7, 249–274 (2008)PubMedCrossRef

J.R. Mola, Erectile dysfunction in the older adult male. Urol. Nurs. 35, 87–93 (2015)PubMedCrossRef

NIH Consensus Conference. Impotence. NIH consensus development panel on impotence. JAMA 270, 83–90 (1993)CrossRef

I.A. Ayta, J.B. McKinlay, R.J. Krane, The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int. 84, 50–56 (1999)PubMedCrossRef

S.D. Cohen, The challenge of erectile dysfunction management in the young man. Curr. Urol. Rep. 16, 84 (2015)PubMedCrossRef

10.

A.D. Seftel, P. Sun, R. Swindle, The prevalence of hypertension, hyperlipidemia, diabetes mellitus and depression in men with erectile dysfunction. J. Urol. 171, 2341–2345 (2004)PubMedCrossRef

11.

R.W. Lewis, K.S. Fugl-Meyer, G. Corona, R.D. Hayes, E.O. Laumann, E.D. Moreira Jr., A.H. Rellini, T. Segraves, Definitions/epidemiology/risk factors for sexual dysfunction. J. Sex. Med. 7, 1598–1607 (2010)PubMedCrossRef

12.

C.G. Bacon, M.A. Mittleman, I. Kawachi, E. Giovannucci, D.B. Glasser, E.B. Rimm, Sexual function in men older than 50 years of age: results from the health professionals follow-up study. Ann. Intern. Med. 139, 161–168 (2003)PubMedCrossRef

13.

Y.C. Huang, C.C. Chin, C.S. Chen, A.W. Shindel, D.R. Ho, C.S. Lin, C.S. Shi, Chronic cigarette smoking impairs erectile function through increased oxidative stress and apoptosis, decreased nNOS, endothelial and smooth muscle contents in a rat model. PLoS ONE 10, e0140728 (2015)PubMedPubMedCentralCrossRef

14.

M.J. Pagano, A. De Fazio, A. Levy, A. RoyChoudhury, P.J. Stahl, Age, body mass index, and frequency of sexual activity are independent predictors of testosterone deficiency in men with erectile dysfunction. Urology 90, 112–118 (2016)PubMedCrossRef

15.

J. Buvat, M. Maggi, L. Gooren, A.T. Guay, J. Kaufman, A. Morgentaler, C. Schulman, H.M. Tan, L.O. Torres, A. Yassin, M. Zitzmann, Endocrine aspects of male sexual dysfunctions. J. Sex. Med. 7, 1627–1656 (2010)PubMedCrossRef

16.

M. De Rosa, S. Zarrilli, G. Vitale, C. Di Somma, F. Orio, L. Tauchmanova, G. Lombardi, A. Colao, Six months of treatment with cabergoline restores sexual potency in hyperprolactinemic males: an open longitudinal study monitoring nocturnal penile tumescence. J. Clin. Endocrinol. Metab. 89, 621–625 (2004)PubMedCrossRef

17.

W.J. Reiter, A. Pycha, G. Schatzl, A. Pokorny, D.M. Gruber, J.C. Huber, M. Marberger, Dehydroepiandrosterone in the treatment of erectile dysfunction: a prospective, double-blind, randomized, placebo-controlled study. Urology 53, 590–594; discussion 594–595 (1999).

18.

A. Morales, A. Black, L. Emerson, J. Barkin, I. Kuzmarov, A. Day, Androgens and sexual function: a placebo-controlled, randomized, double-blind study of testosterone vs. dehydroepiandrosterone in men with sexual dysfunction and androgen deficiency. Aging Male. 12, 104–112 (2009)PubMedCrossRef

19.

G.E. Krassas, K. Tziomalos, F. Papadopoulou, N. Pontikides, P. Perros, Erectile dysfunction in patients with hyper- and hypothyroidism: how common and should we treat? J. Clin. Endocrinol. Metab. 93, 1815–1819 (2008)PubMedCrossRef

20.

A. Veronelli, A. Masu, R. Ranieri, C. Rognoni, M. Laneri, A.E. Pontiroli, Prevalence of erectile dysfunction in thyroid disorders: comparison with control subjects and with obese and diabetic patients. Int. J. Impot. Res. 18, 111–114 (2006)PubMedCrossRef

21.

M. Caprio, C. Mammi, I.Z. Jaffe, M.C. Zennaro, A. Aversa, M.E. Mendelsohn, A. Fabbri, G.M. Rosano, The mineralocorticoid receptor in endothelial physiology and disease: novel concepts in the understanding of erectile dysfunction. Curr. Pharm. Des. 14, 3749–3757 (2008)PubMedCrossRef

22.

T. Kishimoto, T. Fukawa, K. Yamaguchi, Y. Yamamoto, H. Nakatsuji, H. Izaki, M. Takahashi, T. Fukumori, H.O. Kanayama, Mineralocorticoid receptor expression in human penile corpus cavernosum. J. Med. Invest. 60, 21–26 (2013)PubMedCrossRef

23.

H. Muguruma, Y. Kawanishi, H. Sugiyama, J. Kagawa, S. Tanimoto, M. Yamanaka, K. Kojima, H. Anzai, A. Numata, T. Kishimoto, H.O. Kanayama, Effect of aldosterone on isolated human penile corpus cavernosum tissue. BJU Int. 102, 500–503 (2008)PubMedCrossRef

24.

F. Wu, S. Mao, T. Yu, H. Jiang, Q. Ding, G. Xu, Elevated plasma aldosterone is an independent risk factor for erectile dysfunction in men. World J. Urol. 34, 999–1007 (2016).PubMedCrossRef

25.

C. Hellal-Levy, J. Fagart, A. Souque, M.E. Rafestin-Oblin, Mechanistic aspects of mineralocorticoid receptor activation. Kidney Int. 57, 1250–1255 (2000)PubMedCrossRef

26.

M. Bader, Tissue renin-angiotensin-aldosterone systems: targets for pharmacological therapy. Annu. Rev. Pharmacol. Toxicol. 50, 439–465 (2010)PubMedCrossRef

27.

M.D. Taves, C.E. Gomez-Sanchez, K.K. Soma, Extra-adrenal glucocorticoids and mineralocorticoids: evidence for local synthesis, regulation, and function. Am. J. Physiol. Endocrinol. Metab. 301, E11–E24 (2011)PubMedPubMedCentralCrossRef

28.

L.G. Palmer, G. Frindt, Na+and K+transport by the renal connecting tubule. Curr. Opin. Nephrol. Hypertens. 16, 477–483 (2007)PubMedCrossRef

29.

R. Soundararajan, D. Melters, I.C. Shih, J. Wang, D. Pearce, Epithelial sodium channel regulated by differential composition of a signaling complex. Proc. Natl Acad. Sci. USA 106, 7804–7809 (2009)PubMedCrossRef

30.

R. Soundararajan, T. Ziera, E. Koo, K. Ling, J. Wang, S.A. Borden, D. Pearce, Scaffold protein connector enhancer of kinase suppressor of Ras isoform 3 (CNK3) coordinates assembly of a multiprotein epithelial sodium channel (ENaC)-regulatory complex. J. Biol. Chem. 287, 33014–33025 (2012)PubMedPubMedCentralCrossRef

31.

G. Frindt, Z. Ergonul, L.G. Palmer, Surface expression of epithelial Na channel protein in rat kidney. J. Gen. Physiol. 131, 617–627 (2008)PubMedPubMedCentralCrossRef

32.

D. Pearce, R. Soundararajan, C. Trimpert, O.B. Kashlan, P.M. Deen, D.E. Kohan, Collecting duct principal cell transport processes and their regulation. Clin. J. Am. Soc. Nephrol. 10, 135–146 (2015)PubMedCrossRef

33.

F. Verrey, E. Schaerer, P. Zoerkler, M.P. Paccolat, K. Geering, J.P. Kraehenbuhl, B.C. Rossier, Regulation by aldosterone of Na+,K+-ATPase mRNAs, protein synthesis, and sodium transport in cultured kidney cells. J. Cell Biol. 104, 1231–1237 (1987)PubMedCrossRef

34.

A. Odermatt, D.V. Kratschmar, Tissue-specific modulation of mineralocorticoid receptor function by 11beta-hydroxysteroid dehydrogenases: an overview. Mol. Cell. Endocrinol. 350, 168–186 (2012)PubMedCrossRef

35.

N. Farman, M.E. Rafestin-Oblin, Multiple aspects of mineralocorticoid selectivity. Am. J. Physiol. Ren. Physiol. 280, F181–F192 (2001)CrossRef

36.

J. Huyet, G.M. Pinon, M.R. Fay, M.E. Rafestin-Oblin, J. Fagart, Structural determinants of ligand binding to the mineralocorticoid receptor. Mol. Cell. Endocrinol. 350, 187–195 (2012)PubMedCrossRef

37.

M. Caprio, B.G. Newfell, A. la Sala, W. Baur, A. Fabbri, G. Rosano, M.E. Mendelsohn, I.Z. Jaffe, Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion. Circ. Res. 102, 1359–1367 (2008)PubMedPubMedCentralCrossRef

38.

J.W. Funder, P.T. Pearce, R. Smith, A.I. Smith, Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 242, 583–585 (1988)PubMedCrossRef

39.

L.A. Calo, F. Zaghetto, E. Pagnin, P.A. Davis, P. De Mozzi, P. Sartorato, G. Martire, C. Fiore, D. Armanini, Effect of aldosterone and glycyrrhetinic acid on the protein expression of PAI-1 andp22(phox) in human mononuclear leukocytes. J. Clin. Endocrinol. Metab. 89, 1973–1976 (2004)PubMedCrossRef

40.

A. Sato, J.W. Funder, High glucose stimulates aldosterone-induced hypertrophy via type I mineralocorticoid receptors in neonatal rat cardiomyocytes. Endocrinology 137, 4145–4153 (1996)PubMedCrossRef

41.

M. Lombes, M.E. Oblin, J.M. Gasc, E.E. Baulieu, N. Farman, J.P. Bonvalet, Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor. Circ. Res. 71, 503–510 (1992)PubMedCrossRef

42.

Q.N. Dinh, T.V. Arumugam, M.J. Young, G.R. Drummond, C.G. Sobey, S. Chrissobolis, Aldosterone and the mineralocorticoid receptor in the cerebral circulation and stroke. Exp. Transl. Stroke Med. 4, 21 (2012)PubMedPubMedCentralCrossRef

43.

C.E. Gomez-Sanchez, M.Y. Zhou, E.N. Cozza, H. Morita, M.F. Foecking, E.P. Gomez-Sanchez, Aldosterone biosynthesis in the rat brain. Endocrinology 138, 3369–3373 (1997)PubMedCrossRef

44.

Q.N. Dinh, M.J. Young, M.A. Evans, G.R. Drummond, C.G. Sobey, S. Chrissobolis, Aldosterone-induced oxidative stress and inflammation in the brain are mediated by the endothelial cell mineralocorticoid receptor. Brain Res. 1637, 146–153 (2016)PubMedCrossRef

45.

C.T. Tsai, F.T. Chiang, C.D. Tseng, J.J. Hwang, K.T. Kuo, C.K. Wu, C.C. Yu, Y.C. Wang, L.P. Lai, J.L. Lin, Increased expression of mineralocorticoid receptor in human atrial fibrillation and a cellular model of atrial fibrillation. J. Am. Coll. Cardiol. 55, 758–770 (2010)PubMedCrossRef

46.

B.J. He, M.L. Joiner, M.V. Singh, E.D. Luczak, P.D. Swaminathan, O.M. Koval, W. Kutschke, C. Allamargot, J. Yang, X. Guan, K. Zimmerman, I.M. Grumbach, R.M. Weiss, D.R. Spitz, C.D. Sigmund, W.M. Blankesteijn, S. Heymans, P.J. Mohler, M.E. Anderson, Oxidation of CaMKII determines the cardiotoxic effects of aldosterone. Nat. Med. 17, 1610–1618 (2011)PubMedPubMedCentralCrossRef

47.

N. Lalevee, M.C. Rebsamen, S. Barrere-Lemaire, E. Perrier, J. Nargeot, J.P. Benitah, M.F. Rossier, Aldosterone increases T-type calcium channel expression and in vitro beating frequency in neonatal rat cardiomyocytes. Cardiovasc. Res. 67, 216–224 (2005)PubMedCrossRef

48.

J.G. Burniston, A. Saini, L.B. Tan, D.F. Goldspink, Aldosterone induces myocyte apoptosis in the heart and skeletal muscles of rats in vivo. J. Mol. Cell. Cardiol. 39, 395–399 (2005)PubMedCrossRef

49.

P. Du Bois, C. Pablo Tortola, D. Lodka, M. Kny, F. Schmidt, K. Song, S. Schmidt, R. Bassel-Duby, E.N. Olson, J. Fielitz, Angiotensin II induces skeletal muscle atrophy by activating TFEB-mediated MuRF1 expression. Circ. Res. 117, 424–436 (2015)PubMedPubMedCentralCrossRef

50.

A.P. Johnston, J. Baker, M. De Lisio, G. Parise, Skeletal muscle myoblasts possess a stretch-responsive local angiotensin signalling system. J. Renin. Angiotensin. Aldosterone. Syst. 12, 75–84 (2011)PubMedCrossRef

51.

A. Bergmann, C. Eulenberg, M. Wellner, S. Rolle, F. Luft, R. Kettritz, Aldosterone abrogates nuclear factor kappaB-mediated tumor necrosis factor alpha production in human neutrophils via the mineralocorticoid receptor. Hypertension 55, 370–379 (2010)PubMedCrossRef

52.

A. Vinh, W. Chen, Y. Blinder, D. Weiss, W.R. Taylor, J.J. Goronzy, C.M. Weyand, D.G. Harrison, T.J. Guzik, Inhibition and genetic ablation of the B7/CD28 T-cell costimulation axis prevents experimental hypertension. Circulation 122, 2529–2537 (2010)PubMedPubMedCentralCrossRef

53.

T.J. Guzik, N.E. Hoch, K.A. Brown, L.A. McCann, A. Rahman, S. Dikalov, J. Goronzy, C. Weyand, D.G. Harrison, Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J. Exp. Med. 204, 2449–2460 (2007)PubMedPubMedCentralCrossRef

54.

A.A. Herrada, F.J. Contreras, N.P. Marini, C.A. Amador, P.A. Gonzalez, C.M. Cortes, C.A. Riedel, C.A. Carvajal, F. Figueroa, L.F. Michea, C.E. Fardella, A.M. Kalergis, Aldosterone promotes autoimmune damage by enhancing Th17-mediated immunity. J. Immunol. 184, 191–202 (2010)PubMedCrossRef

55.

D.A. Kasal, T. Barhoumi, M.W. Li, N. Yamamoto, E. Zdanovich, A. Rehman, M.F. Neves, P. Laurant, P. Paradis, E.L. Schiffrin, T regulatory lymphocytes prevent aldosterone-induced vascular injury. Hypertension 59, 324–330 (2012)PubMedCrossRef

56.

M. Lombes, N. Farman, J.P. Bonvalet, M.C. Zennaro, Identification and role of aldosterone receptors in the cardiovascular system. Ann. Endocrinol. 61, 41–46 (2000)

57.

Q. Pu, M.F. Neves, A. Virdis, R.M. Touyz, E.L. Schiffrin, Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling. Hypertension 42, 49–55 (2003)PubMedCrossRef

58.

R. Rocha, A.E. Rudolph, G.E. Frierdich, D.A. Nachowiak, B.K. Kekec, E.A. Blomme, E.G. McMahon, J.A. Delyani, Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am. J. Physiol. Heart Circ. Physiol. 283, H1802–H1810 (2002)PubMedCrossRef

59.

Y. Sun, J. Zhang, L. Lu, S.S. Chen, M.T. Quinn, K.T. Weber, Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am. J. Pathol. 161, 1773–1781 (2002)PubMedPubMedCentralCrossRef

60.

I.Z. Jaffe, M.E. Mendelsohn, Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circ. Res. 96, 643–650 (2005)PubMedCrossRef

61.

I.Z. Jaffe, Y. Tintut, B.G. Newfell, L.L. Demer, M.E. Mendelsohn, Mineralocorticoid receptor activation promotes vascular cell calcification. Arterioscler. Thromb. Vasc. Biol. 27, 799–805 (2007)PubMedCrossRef

62.

B.J. Waddell, S. Hisheh, Z.S. Krozowski, P.J. Burton, Localization of 11beta-hydroxysteroid dehydrogenase types 1 and 2 in the male reproductive tract. Endocrinology 144, 3101–3106 (2003)PubMedCrossRef

63.

F. Wu, Z.Q. Xiong, S.H. Mao, J.M. Hu, J.Q. Wang, H.W. Jiang, Q. Ding, Aldosterone induces inflammatory cytokines in penile corpus cavernosum by activating the NF-kappaB pathway. Asian J. Androl. 20, 24–29 (2018)PubMedCrossRef

64.

R.F. Reilly, D.H. Ellison, Mammalian distal tubule: physiology, pathophysiology, and molecular anatomy. Physiol. Rev. 80, 277–313 (2000)PubMedCrossRef

65.

M.K. Rude, T.A. Duhaney, G.M. Kuster, S. Judge, J. Heo, W.S. Colucci, D.A. Siwik, F. Sam, Aldosterone stimulates matrix metalloproteinases and reactive oxygen species in adult rat ventricular cardiomyocytes. Hypertension 46, 555–561 (2005)PubMedCrossRef

66.

S. Johar, A.C. Cave, A. Narayanapanicker, D.J. Grieve, A.M. Shah, Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase. Faseb. J. 20, 1546–1548 (2006)PubMedCrossRef

67.

S. Keidar, M. Kaplan, E. Pavlotzky, R. Coleman, T. Hayek, S. Hamoud, M. Aviram, Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone. Circulation 109, 2213–2220 (2004)PubMedCrossRef

68.

F. Iwashima, T. Yoshimoto, I. Minami, M. Sakurada, Y. Hirono, Y. Hirata, Aldosterone induces superoxide generation via Rac1 activation in endothelial cells. Endocrinology 149, 1009–1014 (2008)PubMedCrossRef

69.

J.A. Leopold, A. Dam, B.A. Maron, A.W. Scribner, R. Liao, D.E. Handy, R.C. Stanton, B. Pitt, J. Loscalzo, Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat. Med. 13, 189–197 (2007)PubMedPubMedCentralCrossRef

70.

Y. Yuan, Y. Chen, P. Zhang, S. Huang, C. Zhu, G. Ding, B. Liu, T. Yang, A. Zhang, Mitochondrial dysfunction accounts for aldosterone-induced epithelial-to-mesenchymal transition of renal proximal tubular epithelial cells. Free Radic. Biol. Med. 53, 30–43 (2012)PubMedCrossRef

71.

A. Zhang, Z. Jia, X. Guo, T. Yang, Aldosterone induces epithelial-mesenchymal transition via ROS of mitochondrial origin. Am. J. Physiol. Ren. Physiol. 293, F723–F731 (2007)CrossRef

72.

C. Zhu, S. Huang, Y. Yuan, G. Ding, R. Chen, B. Liu, T. Yang, A. Zhang, Mitochondrial dysfunction mediates aldosterone-induced podocyte damage: a therapeutic target of PPARgamma. Am. J. Pathol. 178, 2020–2031 (2011)PubMedPubMedCentralCrossRef

73.

V.C. De Giusti, M.B. Nolly, A.M. Yeves, C.I. Caldiz, M.C. Villa-Abrille, G.E. Chiappe de Cingolani, I.L. Ennis, H.E. Cingolani, E.A. Aiello, Aldosterone stimulates the cardiac Na(+)/H(+) exchanger via transactivation of the epidermal growth factor receptor. Hypertension 58, 912–919 (2011)PubMedCrossRef

74.

V.C. De Giusti, A. Orlowski, M.C. Ciancio, M.S. Espejo, L.A. Gonano, C.I. Caldiz, M.G. Vila Petroff, M.C. Villa-Abrille, E.A. Aiello, Aldosterone stimulates the cardiac sodium/bicarbonate cotransporter via activation of the g protein-coupled receptor gpr30. J. Mol. Cell. Cardiol. 89, 260–267 (2015)PubMedCrossRef

75.

T.Y. Chun, L.J. Bloem, J.H. Pratt, Aldosterone inhibits inducible nitric oxide synthase in neonatal rat cardiomyocytes. Endocrinology 144, 1712–1717 (2003)PubMedCrossRef

76.

D. Nagata, M. Takahashi, K. Sawai, T. Tagami, T. Usui, A. Shimatsu, Y. Hirata, M. Naruse, Molecular mechanism of the inhibitory effect of aldosterone on endothelial NO synthase activity. Hypertension 48, 165–171 (2006)PubMedCrossRef

77.

E.H. Bae, H.J. Cho, I.J. Kim, S.Y. Joo, J.H. Shin, S.K. Ma, J. Lee, S.W. Kim, Altered regulation of renal nitric oxide, atrial natriuretic peptide and cyclooxygenase systems in aldosterone escape in rats. Regul. Pept. 159, 117–122 (2010)PubMedCrossRef

78.

H.M. Thai, B.Q. Do, T.D. Tran, M.A. Gaballa, S. Goldman, Aldosterone antagonism improves endothelial-dependent vasorelaxation in heart failure via upregulation of endothelial nitric oxide synthase production. J. Card. Fail. 12, 240–245 (2006)PubMedCrossRef

79.

C.J. Hanke, T. O’Brien, K.A. Pritchard Jr., W.B. Campbell, Inhibition of adrenal cell aldosterone synthesis by endogenous nitric oxide release. Hypertension 35, 324–328 (2000)PubMedCrossRef

80.

J.A. Muldowney 3rd, S.N. Davis, D.E. Vaughan, N.J. Brown, NO synthase inhibition increases aldosterone in humans. Hypertension 44, 739–745 (2004)PubMedCrossRef

81.

J.M. Sainz, C. Reche, M.A. Rabano, C. Mondillo, Z.J. Patrignani, J.M. Macarulla, O.P. Pignataro, M. Trueba, Effects of nitric oxide on aldosterone synthesis and nitric oxide synthase activity in glomerulosa cells from bovine adrenal gland. Endocrine 24, 61–71 (2004)PubMedCrossRef

82.

C.J. Hanke, W.B. Campbell, Endothelial cell nitric oxide inhibits aldosterone synthesis in zona glomerulosa cells: modulation by oxygen. Am. J. Physiol. Endocrinol. Metab. 279, E846–E854 (2000)PubMedCrossRef

83.

Le.T.Y. Loan, M. Mardini, V.M. Howell, J.W. Funder, A.W. Ashton, A.S. Mihailidou, Low-dose spironolactone prevents apoptosis repressor with caspase recruitment domain degradation during myocardial infarction. Hypertension 59, 1164–1169 (2012)CrossRef

84.

T.A. Williams, A. Verhovez, A. Milan, F. Veglio, P. Mulatero, Protective effect of spironolactone on endothelial cell apoptosis. Endocrinology 147, 2496–2505 (2006)PubMedCrossRef

85.

Y. Nakamura, S. Suzuki, T. Suzuki, K. Ono, I. Miura, F. Satoh, T. Moriya, H. Saito, S. Yamada, S. Ito, H. Sasano, MDM2: a novel mineralocorticoid-responsive gene involved in aldosterone-induced human vascular structural remodeling. Am. J. Pathol. 169, 362–371 (2006)PubMedPubMedCentralCrossRef

86.

C. Crochemore, J. Lu, Y. Wu, Z. Liposits, N. Sousa, F. Holsboer, O.F. Almeida, Direct targeting of hippocampal neurons for apoptosis by glucocorticoids is reversible by mineralocorticoid receptor activation. Mol. Psychiatry 10, 790–798 (2005)PubMedCrossRef

87.

T. Nakamura, K. Kataoka, M. Fukuda, H. Nako, Y. Tokutomi, Y.F. Dong, H. Ichijo, H. Ogawa, S. Kim-Mitsuyama, Critical role of apoptosis signal-regulating kinase 1 in aldosterone/salt-induced cardiac inflammation and fibrosis. Hypertension 54, 544–551 (2009)PubMedCrossRef

88.

Y. Wei, A.T. Whaley-Connell, J. Habibi, J. Rehmer, N. Rehmer, K. Patel, M. Hayden, V. DeMarco, C.M. Ferrario, J.A. Ibdah, J.R. Sowers, Mineralocorticoid receptor antagonism attenuates vascular apoptosis and injury via rescuing protein kinase B activation. Hypertension 53, 158–165 (2009)PubMedCrossRef

89.

N. Queisser, N. Schupp, Aldosterone, oxidative stress, and NF-kappaB activation in hypertension-related cardiovascular and renal diseases. Free Radic. Biol. Med. 53, 314–327 (2012)PubMedCrossRef

90.

N. Queisser, N. Schupp, H. Stopper, R. Schinzel, P.I. Oteiza, Aldosterone increases kidney tubule cell oxidants through calcium-mediated activation of NADPH oxidase and nitric oxide synthase. Free Radic. Biol. Med. 51, 1996–2006 (2011)PubMedCrossRef

91.

V. Leroy, S. De Seigneux, V. Agassiz, U. Hasler, M.E. Rafestin-Oblin, M. Vinciguerra, P.Y. Martin, E. Feraille, Aldosterone activates NF-kappaB in the collecting duct. J. Am. Soc. Nephrol. 20, 131–144 (2009)PubMedPubMedCentralCrossRef

92.

S.U. Sonder, A. Woetmann, N. Odum, K. Bendtzen, Spironolactone induces apoptosis and inhibits NF-kappaB independent of the mineralocorticoid receptor. Apoptosis 11, 2159–2165 (2006)PubMedCrossRef

93.

J.C. Reil, M. Hohl, S. Selejan, P. Lipp, F. Drautz, A. Kazakow, B.M. Munz, P. Muller, P. Steendijk, G.H. Reil, M.A. Allessie, M. Bohm, H.R. Neuberger, Aldosterone promotes atrial fibrillation. Eur. Heart J. 33, 2098–2108 (2012)PubMedCrossRef

94.

G.M. Kuster, E. Kotlyar, M.K. Rude, D.A. Siwik, R. Liao, W.S. Colucci, F. Sam, Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload. Circulation 111, 420–427 (2005)PubMedCrossRef

95.

A. Di Zhang, A. Nguyen Dinh Cat, C. Soukaseum, B. Escoubet, A. Cherfa, S. Messaoudi, C. Delcayre, J.L. Samuel, F. Jaisser, Cross-talk between mineralocorticoid and angiotensin II signaling for cardiac remodeling. Hypertension 52, 1060–1067 (2008)PubMedCrossRef

96.

G. Suzuki, H. Morita, T. Mishima, V.G. Sharov, A. Todor, E.J. Tanhehco, A.E. Rudolph, E.G. McMahon, S. Goldstein, H.N. Sabbah, Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation 106, 2967–2972 (2002)PubMedCrossRef

97.

M.R. Ward, P. Kanellakis, D. Ramsey, J. Funder, A. Bobik, Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries. Circulation 104, 467–472 (2001)PubMedCrossRef

98.

J. Qu, F.M. Volpicelli, L.I. Garcia, N. Sandeep, J. Zhang, L. Marquez-Rosado, P.D. Lampe, G.I. Fishman, Gap junction remodeling and spironolactone-dependent reverse remodeling in the hypertrophied heart. Circ. Res. 104, 365–371 (2009)PubMedCrossRef

99.

P. Mulder, V. Mellin, J. Favre, M. Vercauteren, I. Remy-Jouet, C. Monteil, V. Richard, S. Renet, J.P. Henry, A.Y. Jeng, R.L. Webb, C. Thuillez, Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone. Eur. Heart J. 29, 2171–2179 (2008)PubMedCrossRef

100.

G.P. Vyssoulis, E.A. Karpanou, V.E. Tzamou, S.M. Kyvelou, A.P. Michaelidis, T.P. Gialernios, D.V. Cokkinos, C.I. Stefanadis, Aldosterone levels and stroke incidence in essential hypertensive patients. Int. J. Cardiol. 144, 171–172 (2010)PubMedCrossRef

101.

B.S. Huang, F.H. Leenen, The brain renin-angiotensin-aldosterone system: a major mechanism for sympathetic hyperactivity and left ventricular remodeling and dysfunction after myocardial infarction. Curr. Heart Fail. Rep. 6, 81–88 (2009)PubMedCrossRef

102.

M. Joels, H. Karst, R. DeRijk, E.R. de Kloet, The coming out of the brain mineralocorticoid receptor. Trends Neurosci. 31, 1–7 (2008)PubMedCrossRef

103.

E.A. Young, J.F. Lopez, V. Murphy-Weinberg, S.J. Watson, H. Akil, Mineralocorticoid receptor function in major depression. Arch. Gen. Psychiatry 60, 24–28 (2003)PubMedCrossRef

104.

C. Otte, K. Wingenfeld, L.K. Kuehl, S. Richter, F. Regen, D. Piber, K. Hinkelmann, Cognitive function in older adults with major depression: Effects of mineralocorticoid receptor stimulation. J. Psychiatr. Res. 69, 120–125 (2015)PubMedCrossRef

105.

V.S. Chhokar, Y. Sun, S.K. Bhattacharya, R.A. Ahokas, L.K. Myers, Z. Xing, R.A. Smith, I.C. Gerling, K.T. Weber, Hyperparathyroidism and the calcium paradox of aldosteronism. Circulation 111, 871–878 (2005)PubMedCrossRef

106.

Y. Mizuno, M. Yoshimura, H. Yasue, T. Sakamoto, H. Ogawa, K. Kugiyama, E. Harada, M. Nakayama, S. Nakamura, T. Ito, Y. Shimasaki, Y. Saito, K. Nakao, Aldosterone production is activated in failing ventricle in humans. Circulation 103, 72–77 (2001)PubMedCrossRef

107.

G. Guder, J. Bauersachs, S. Frantz, D. Weismann, B. Allolio, G. Ertl, C.E. Angermann, S. Stork, Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation 115, 1754–1761 (2007)PubMedCrossRef

108.

F.M. Gutierrez-Marcos, A. Fernandez-Cruz, J. Gutkowska, C. Herrero, A. Blesa, V. Estrada, C. Loscos, J.M. Lopez-Novoa, Atrial natriuretic peptide in patients with acute myocardial infarction without functional heart failure. Eur. Heart J. 12, 503–507 (1991)PubMedCrossRef

109.

F. Beygui, J.P. Collet, J.J. Benoliel, N. Vignolles, R. Dumaine, O. Barthelemy, G. Montalescot, High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction. Circulation 114, 2604–2610 (2006)PubMedCrossRef

110.

B. Pitt, W. Remme, F. Zannad, J. Neaton, F. Martinez, B. Roniker, R. Bittman, S. Hurley, J. Kleiman, M. Gatlin, Eplerenone Post-Acute Myocardial Infarction Heart Failure E, Survival Study I, Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 348, 1309–1321 (2003).PubMedCrossRef

111.

B. Pitt, F. Zannad, W.J. Remme, R. Cody, A. Castaigne, A. Perez, J. Palensky, J. Wittes, The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 341, 709–717 (1999)PubMedCrossRef

112.

M.B. Nolly, C.I. Caldiz, A.M. Yeves, M.C. Villa-Abrille, P.E. Morgan, N. Amado Mondaca, E.L. Portiansky, G.E. Chiappe de Cingolani, H.E. Cingolani, I.L. Ennis, The signaling pathway for aldosterone-induced mitochondrial production of superoxide anion in the myocardium. J. Mol. Cell. Cardiol. 67, 60–68 (2014)PubMedCrossRef

113.

B.R. Palmer, A.P. Pilbrow, C.M. Frampton, T.G. Yandle, L. Skelton, M.G. Nicholls, A.M. Richards, Plasma aldosterone levels during hospitalization are predictive of survival post-myocardial infarction. Eur. Heart J. 29, 2489–2496 (2008)PubMedCrossRef

114.

M. Quinkler, D. Zehnder, K.S. Eardley, J. Lepenies, A.J. Howie, S.V. Hughes, P. Cockwell, M. Hewison, P.M. Stewart, Increased expression of mineralocorticoid effector mechanisms in kidney biopsies of patients with heavy proteinuria. Circulation 112, 1435–1443 (2005)PubMedCrossRef

115.

J.P. Bertocchio, D.G. Warnock, F. Jaisser, Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease. Kidney Int. 79, 1051–1060 (2011)PubMedCrossRef

116.

K. Ando, H. Ohtsu, S. Uchida, S. Kaname, Y. Arakawa, T. Fujita, E.S. Group, Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2, 944–953 (2014)PubMedCrossRef

117.

G.L. Bakris, R. Agarwal, J.C. Chan, M.E. Cooper, R.T. Gansevoort, H. Haller, G. Remuzzi, P. Rossing, R.E. Schmieder, C. Nowack, P. Kolkhof, A. Joseph, A. Pieper, N. Kimmeskamp-Kirschbaum, L.M. Ruilope; Mineralocorticoid Receptor Antagonist Tolerability Study-Diabetic Nephropathy Study G., Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA 314, 884–894 (2015)PubMedCrossRef

118.

T. Kosugi, M. Heinig, T. Nakayama, S. Matsuo, T. Nakagawa, eNOS knockout mice with advanced diabetic nephropathy have less benefit from renin-angiotensin blockade than from aldosterone receptor antagonists. Am. J. Pathol. 176, 619–629 (2010)PubMedPubMedCentralCrossRef

119.

T. Suehiro, K. Tsuruya, H. Ikeda, J. Toyonaga, S. Yamada, H. Noguchi, M. Tokumoto, T. Kitazono, Systemic aldosterone, but not angiotensin II, plays a pivotal role in the pathogenesis of renal injury in chronic nitric oxide-deficient male rats. Endocrinology 156, 2657–2666 (2015).PubMedCrossRef

120.

B. Musicki, A.J. Bella, T.J. Bivalacqua, K.P. Davies, M.E. DiSanto, N.F. Gonzalez-Cadavid, J.L. Hannan, N.N. Kim, C.A. Podlasek, C.J. Wingard, A.L. Burnett, Basic science evidence for the link between erectile dysfunction and cardiometabolic dysfunction. J. Sex. Med. 12, 2233–2255 (2015)PubMedPubMedCentralCrossRef

121.

J.T. Clark, A. Sahu, J.J. Mrotek, S.P. Kalra, Sexual function and neuropeptide Y levels in selected brain regions in male spontaneously hypertensive rats. Am. J. Physiol. 261, R1234–R1241 (1991)PubMed

122.

F. Wu, S. Mao, T. Yu, H. Jiang, Q. Ding, G. Xu, Elevated plasma aldosterone is an independent risk factor for erectile dysfunction in men. World J. Urol. 34, 999–1007 (2016)PubMedCrossRef

123.

F.A. DeLano, G.W. Schmid-Schonbein, Enhancement of glucocorticoid and mineralocorticoid receptor density in the microcirculation of the spontaneously hypertensive rat. Microcirculation 11, 69–78 (2004)PubMedCrossRef

124.

M. Zhao, I. Celerier, E. Bousquet, J.C. Jeanny, L. Jonet, M. Savoldelli, O. Offret, A. Curan, N. Farman, F. Jaisser, F. Behar-Cohen, Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J. Clin. Invest. 122, 2672–2679 (2012)PubMedPubMedCentralCrossRef

125.

M. Lainscak, F. Pelliccia, G. Rosano, C. Vitale, M. Schiariti, C. Greco, G. Speziale, C. Gaudio, Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone. Int. J. Cardiol. 200, 25–29 (2015)PubMedCrossRef

126.

H.S. Zarren, P.M. Black, Unilateral gynecomastia and impotence during low-dose spironolactone administration in men. Mil. Med. 140, 417–419 (1975)PubMedCrossRef

127.

D.J. Greenblatt, J. Koch-Weser, Gynecomastia and impotence: complications of spironolactone therapy. JAMA 223, 82 (1973)PubMedCrossRef

128.

M. Epstein, D.A. Calhoun, Aldosterone blockers (mineralocorticoid receptor antagonism) and potassium-sparing diuretics. J. Clin. Hypertens. 13, 644–648 (2011)CrossRef

129.

C. Bonne, J.P. Raynaud, Mode of spironolactone anti-androgenic action: inhibition of androstanolone binding to rat prostate androgen receptor. Mol. Cell. Endocrinol. 2, 59–67 (1974)PubMedCrossRef

130.

F. Zannad, J.J. McMurray, H. Krum, D.J. van Veldhuisen, K. Swedberg, H. Shi, J. Vincent, S.J. Pocock, B. Pitt, E.-H.S. Group, Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 364, 11–21 (2011)PubMedCrossRef

131.

B. Pitt, L. Kober, P. Ponikowski, M. Gheorghiade, G. Filippatos, H. Krum, C. Nowack, P. Kolkhof, S.Y. Kim, F. Zannad, Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur. Heart J. 34, 2453–2463 (2013)PubMedPubMedCentralCrossRef

132.

M. Hargovan, A. Ferro, Aldosterone synthase inhibitors in hypertension: current status and future possibilities. JRSM Cardiovasc. Dis. 3, 2048004014522440 (2014)PubMedPubMedCentral

133.

A. Fiebeler, J. Nussberger, E. Shagdarsuren, S. Rong, G. Hilfenhaus, N. Al-Saadi, R. Dechend, M. Wellner, S. Meiners, C. Maser-Gluth, A.Y. Jeng, R.L. Webb, F.C. Luft, D.N. Muller, Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation 111, 3087–3094 (2005)PubMedCrossRef

134.

X. Bertagna, R. Pivonello, M. Fleseriu, Y. Zhang, P. Robinson, A. Taylor, C.E. Watson, M. Maldonado, A.H. Hamrahian, M. Boscaro, B.M. Biller, LCI699, a potent 11beta-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing’s disease: results from a multicenter, proof-of-concept study. J. Clin. Endocrinol. Metab. 99, 1375–1383 (2014)PubMedCrossRef

135.

A. Granata, G. Tirabassi, V. Pugni, G. Arnaldi, M. Boscaro, C. Carani, G. Balercia, Sexual dysfunctions in men affected by autoimmune Addison’s disease before and after short-term gluco- and mineralocorticoid replacement therapy. J. Sex. Med. 10, 2036–2043 (2013)PubMedCrossRef

Titel: The emerging role of aldosterone/mineralocorticoid receptors in the pathogenesis of erectile dysfunction
verfasst von: Fei Wu
Yun Lin
Qingyong Liu
Publikationsdatum: 02.05.2018
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 3/2018
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-018-1610-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

17.04.2024 | DGIM 2024 | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

The emerging role of aldosterone/mineralocorticoid receptors in the pathogenesis of erectile dysfunction

Abstract

Purpose

Methods

Results

Conclusion

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Adjuvante Brustkrebstherapie: Doppelt hält besser

Delir kann Demenz begünstigen

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

Update Innere Medizin

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2018

Incidence and management of postoperative hyperglycemia in patients undergoing insulinoma resection

Natural history and clinical characteristics of 50 patients with Wolfram syndrome

Additions of neural monitoring for thyroid surgery

Role of the ubiquitin/proteasome system on ACTH turnover in rat corticotropes

Patients’ knowledge about the outcomes of thyroid biopsy: a patient survey

TERTp mutation is associated with a shorter progression free survival in patients with aggressive histology subtypes of follicular-cell derived thyroid carcinoma

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Adjuvante Brustkrebstherapie: Doppelt hält besser

Delir kann Demenz begünstigen

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

Update Innere Medizin